Skip to main content

Table 2 Included studies: interventions and outcomes assessed in the NMA

From: Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings

Studies included Interventions studied and assessed in the NMA Pain freedom at 2 hours Pain relief at 2 hours Pain relief at 1 hour MBS freedom at 2 hours Sustained pain freedom over 24 hours Pain freedom at 30 min Pain freedom at 1 hour MBS freedom at 1 hour Pain relief at 30 min
Lasmiditan vs placebo
 SAMURAI Kuca et al. 2018 [15] Lasmiditan 100 mg, 200 mg
 SPARTAN Goadsby et al. 2019 [16] Lasmiditan 50 mg, 100 mg, 200 mg
 CENTURION Ashina et al. 2021 [17] Lasmiditan 100 mg, 200 mg
 MONONOFU Sakai et al. 2021 [18] Lasmiditan 50 mg, 100 mg, 200 mg
Färkkilä et al. 2012 [19] Lasmiditan 50 mg, 100 mg, 200 mg        
Rimegepant vs placebo
 Study 301 Lipton et al. 2018 [20] Rimegepant 75 mg tablets       
 Study 302 Lipton et al. 2019 [21] Rimegepant 75 mg tablets       
 Study 303 Croop et al. 2019 [22] Rimegepant 75 mg ODT    
Marcus et al. 2014 [23] Rimegepant 75 mg tablets        
Ubrogepant vs placebo
 ACHIEVE I Dodick et al. 2019 [24] Ubrogepant 50 mg, 100 mg       
 ACHIEVE II Lipton et al. 2019 [25] Ubrogepant 25 mg, 50 mg       
 Voss et al. 2016 [26] Ubrogepant 25 mg, 50 mg, 100 mg        
 ACHIEVE I + ACHIEVE II pooled data Goadsby et al. 2021 [27] Ubrogepant 50 mg    
  1. Bold ticks denote the primary endpoint(s) of the study
  2. MBS most bothersome symptom, NMA network meta-analysis, ODT oral disintegrating tablet